LA JOLLA, Calif., July 11, 2019 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced its plans for a Phase 3 clinical trial of MN-166 (ibudilast) in progressive multiple sclerosis (progressive MS) following feedback from the FDA (U.S. Food and Drug Administration).
News Ticker
- [ July 17, 2019 ] Tocagen Inc.: Associate Director, Quality Control/Technology San Diego Biotech Jobs
- [ July 16, 2019 ] Bristol-Myers Squibb Company: Community Product Specialist I-O San Diego Biotech Jobs
- [ July 16, 2019 ] (Assoc.) Director of CMC Supply Chain – Synthorx, Inc. – La Jolla, CA San Diego Biotech Jobs
- [ July 16, 2019 ] Associate Director of Late-Stage Analytics and Bioassay Development – Synthorx, Inc. – La Jolla, CA San Diego Biotech Jobs
- [ July 16, 2019 ] Lab Manager (Full Time Contractor) – Synthorx, Inc. – La Jolla, CA San Diego Biotech Jobs
Copyright © 2019 San Diego Biotechnology Network (DBA of Comprendia. LLC)
